News Archive

Caplacizumab Update

Feb 6, 2019: The U.S. Food and Drug Administration (FDA) has approved Cablivi® (caplacizumab-yhdp) in combination with plasma exchange and immunosuppression for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in adults.  Cablivi is the first FDA approved therapy specifically indicated for the treatment of aTTP. Full press release here.

Support Groups

Fall 2018 Ohio TTP & aHUS Support Group Meeting

The Ohio State University TTP/aHUS face-to-face meeting was made available to non-local participants to join virtually. On Wednesday November 7th, Dr. Cataland presented a great layman explanation about the role of the ADAMTS13 enzyme in TTP. In addition, he thoughtfully answered questions from both the face-to-face and virtual audiences about TTP triggers, treatments, side effects and more. On an exciting note, he explained the role of a new drug called caplacizumab.

Researcher's Work is Published

Answering TTP Foundation provided research grant funding to support Dr. Long Zheng which has resulted in two research papers on TTP. Together we are furthering the understanding and coming closer to a targeted treatment for TTP. Congratulations Dr. Long Zheng! And congratulations to all supporters of the Answering TTP Foundation.

hTTP Study Recruiting

A healthcare research firm is recruiting patients who have been diagnosed with hereditary (inherited) thrombotic thrombocytopenic purpura (hTTP). hTTP represents about 1% of  TTP cases and is characterized by inherited deficiency or abnormality of the ADAMTS 13 enzyme.

For more information and for participation instructions click here.

Fundraising Initiatives

2018 Chance for Change Game Night

The 9th Annual Chance for Change raised $200,000 on April 21, 2018. Guests were thrilled by our new venue, our wide selection of silent auction items, the fun games, exciting raffles, stunning entertainment and delicious food. 

Listen to the feedback from our guests ----

Research Outcomes

The Answering TTP Foundation's Board of Directors has received impact statements from two Principal Investigators that have completed their Foundation funded grants. The results are encouraging. A patient-led organization plays a vital role in the quest to conquer TTP. Congratulations to our researchers and to all those who support the Foundation.

More information about these research grant outcomes has been uploaded to each grant information page,

Our Condolences

Our heartfelt condolences to the family of the late Max Marin who died 10 days after being diagnosed with TTP. Max lived in Calgary, Alberta. He was a 45-year-old father, husband and well-known MMA trainer. Reports indicate that the TTP diagnosis was missed by the health clinic he visited initially.  Only when his health deteriorated, and his family took him to the main hospital, was he diagnosed with TTP.

Pages